Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
ISEMBYLD
product2 mentionslast seen Nov 10, 2026
A fully human monoclonal IgG4 antibody approved by the FDA for the treatment of spinal muscular atrophy in adults and children 2 years of age and older who are currently receiving an SMN2-targeted treatment.
Relationships 9
- U.S. Food and Drug AdministrationapprovesISEMBYLD99% confidence2 sources
- Scholar Rock Holding CorporationdevelopsISEMBYLD99% confidence2 sources
- ISEMBYLDapplies tospinal muscular atrophy99% confidence1 source
- Scholar Rock Holding CorporationcommercializesISEMBYLD99% confidence1 source
- ISEMBYLDapplies tospinal muscular atrophy treatment96% confidence1 source
- ISEMBYLDimplementsmyostatin inhibition95% confidence1 source
- ISEMBYLDdepends onsurvival motor neuron 2 targeted treatment90% confidence1 source
- ISEMBYLDdepends onmyostatin inhibition85% confidence1 source
- ISEMBYLDcomposed ofmyostatin inhibition80% confidence1 source
Relationship
U.S. Food and Drug AdministrationapprovesISEMBYLD
99% confidence2 supporting mentionsfrom Sep 11, 2026
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 10, 2026Scholar Rock Holding Corp 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.02: Results of Operations and Financial Condition; Item 7.01: Regulation FD Disclosure
upon approval of Scholar Rock's biologics license application for ISEMBYLD™ (apitegromab-mstn)
- filingSEC EDGARSep 14, 2026Scholar Rock Holding Corp 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
the U.S. Food and Drug Administration ("FDA") has approved ISEMBYLD™ (apitegromab-mstn)